Triferic’s Unique Mode-of-Action Highlighted at Innovative Iron Conference

WIXOM, Mich., April 27, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that a poster and oral presentation for Triferic (ferric pyrophosphate citrate)have been selected by the International BioIron Society (IBIS) and will be presented at their 7^th International Congress in Los Angeles, at UCLA, at the Luskin Conference Center, on May 7 – 11, 2017. Triferic is the only FDA approved therapy indicated to replace iron and maintain hemoglobin in chronic kidney disease patients receiving hemodialysis.

Presentation schedule at the BioIron meeting:

Poster Presentation:
No. 70 Pharmacokinetics (Pk) Of Ferric Pyrophosphate Citrate (Triferic): Modeling Diurnal Iron and Additivity Of Triferic In Healthy Volunteers Iron
Raymond Pratt, MD¹, Mark Bush, PhD, Scott Brantley, PhD and Ajay Gupta, MD
Rockwell Medical, Inc., Wixom, MI, USA and Nuventra, Durham, NC
Monday, May, 8, 4:45-7:00PM PDT
                    
Oral Presentation:
Ferric Pyrophosphate Citrate (Triferic), a Novel Therapy that Treats Anemia of Inflammation and Overcomes Functional Iron Deficiency.
Ajay Gupta, MD and Raymond Pratt, MD
Rockwell Medical, Inc., Wixom, MI USA
Thursday, May 11, 3:00PM PDT

The BioIron Meeting is the main international forum for the comprehensive presentation and discussion of cutting-edge advances in the biology of iron and the role of iron in medical science. The knowledge gained from these meetings has had a major translational impact in traditional iron-related disorders such as iron overload and deficiency. Furthermore, an essential role for iron has been recognized in other common disorders, including cancer, cardiovascular, inflammatory and neurodegenerative disorders.

The most recent results and advances in the field will be presented at the meeting. Oral presentations selected from the submitted contributions will present novel unpublished data. For these reasons and for its strong interdisciplinary character the meeting provides a great opportunity to foster collaboration among iron scientists and clinicians.

About Triferic
Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, effectively maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Please visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information.

About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Rockwell’s recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market and globally.

Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.  Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three U.S. manufacturing/distribution facilities.

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to sell and market Calcitriol and Triferic. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Triferic^® is a registered trademark of Rockwell Medical, Inc.

Michael Rice, Investor Relations; 646-597-6979